Picankibart
Based on 1 Customer Validation
Picankibart (IBI112) is a monoclonal antibody targeting IL-23p19. Picankibart has a Kd of 4.806-12 M for human IL-23p19, with an EC50 of 1.4632 nM and an IC50 of 1.2533 nM. Picankibart binds to the IL-23 p19 subunit, blocks the binding of IL-23 to the IL-23 receptor, and inhibits downstream STAT3 phosphorylation and IL-17 production. Picankibart can be used in research on psoriasis and ulcerative colitis.
For research use only. We do not sell to patients.
- Purity : 98.00%
- CAS No.: 2622900-74-5
- Molecular Weight:144.744 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
IL-23 1.2533 nM (IC50) |
IL-23 1.4632 nM (EC50) |
p-STAT3 |
IL-17 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Splenocyte | IC50 |
3.8763 nM
|
Inhibition of human IL-23-induced IL-17 production in mouse C57BL/6 splenocytes incubated with Picankibart for 90 hrs measured by ELISA.
Inhibition of human IL-23-induced IL-17 production in mouse C57BL/6 splenocytes incubated with Picankibart for 90 hrs measured by ELISA.
|
33069927 |
| Splenocyte | IC50 |
12.1950 nM
|
Inhibition of human IL-23-induced IL-17F production in cynomolgus monkey splenocytes incubated with Picankibart for 90 hrs measured by ELISA.
Inhibition of human IL-23-induced IL-17F production in cynomolgus monkey splenocytes incubated with Picankibart for 90 hrs measured by ELISA.
|
33069927 |
In Vitro
Picankibart binds human FcRn in BLI with higher affinity at pH 6.0 (KD = 1.43-10 M) than at pH 7.4 (KD = 6.86-06 M)[1].
Picankibart inhibits IL-23-induced STAT3 phosphorylation in human CD4+ T cells with an IC50 of 87.6133 nM[1].
Picankibart blocks IL-23-induced IL-17 production in mouse splenocytes with an IC50 of 3.8763 nM; it blocks IL-23-induced IL-17F production in cynomolgus monkey splenocytes with an IC50 of 12.1950 nM[1].
Picankibart (20-200 µg/mL; 4-24 h) does not induce significant release of IL-6, IL-8, or TNF-α from human PBMCs[1].
Picankibart (IBI112) is a recombinant IgG1 monoclonal antibody targeting the IL-23p19 subunit and is an optimized IL-23p19 inhibitor[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Picankibart (day 0 and day 3) in combination with an anti-IL-1R antibody prolongs disease-free survival and improves psoriasis scores in the IMQ-induced psoriasis model of human IL-23 knock-in mice, especially in the early stage of the disease[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (female, 6-8 weeks old, 1 μg of IL-23 was injected s.c. into the mouse ears every day for 8 days)[1]
-
Dosage:1 mg/kg
-
Administration:i.p.; once on day -1
-
Result:Reduced IL-23-induced ear swelling and epidermal thickness.
Reduced inflammatory cell infiltration in skin, and microabscesses in the stratum corneum completely regressed.
Parmacokinetics
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Loaded Picankibart on AHC2 biosensor, can bind Human IL-23 alpha & Mouse IL-12 beta Heterodimer Protein (HEK293, His, HY-P74874) with an affinity constant of 7.207E-11 M as determined in BLI assay. -
Flow Cytometry analysis of Raji cells labelling IL-23A (red) with Picankibart (anti-IL-23A) (HY-P990057). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Product Details
-
CAS No. 2622900-74-5
-
Accession Q9NPF7
-
Synonyms IBI112
-
Molecular Weight 144.744 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 kappa
-
Recommend Isotype Controls
-
Format
-
Human IgG1 kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
98.00%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Shipping
Shipping with dry ice.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)